Teladoc Health (NYSE:TDOC) Issues FY24 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of ($1.10)-($0.80) for the period, compared to the consensus EPS estimate of ($1.03). The company issued revenue guidance of $2.635-$2.735 billion, compared to the consensus revenue estimate of $2.66 billion. Teladoc Health also updated its Q2 guidance to ($0.45)-($0.35) EPS.

Teladoc Health Price Performance

Shares of NYSE TDOC traded down $0.32 during mid-day trading on Friday, reaching $13.01. 7,696,741 shares of the company were exchanged, compared to its average volume of 4,813,149. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. The company’s 50-day simple moving average is $15.01 and its 200-day simple moving average is $17.77. Teladoc Health has a twelve month low of $12.65 and a twelve month high of $30.41.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). The firm had revenue of $646.13 million for the quarter, compared to the consensus estimate of $637.31 million. Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. Teladoc Health’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.37) EPS. On average, research analysts predict that Teladoc Health will post -1.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC reissued a hold rating on shares of Teladoc Health in a research report on Friday. Citigroup decreased their target price on shares of Teladoc Health from $21.00 to $19.00 and set a neutral rating on the stock in a research report on Wednesday, February 21st. DA Davidson reduced their price target on Teladoc Health from $22.00 to $18.00 and set a neutral rating on the stock in a research report on Wednesday, February 21st. Canaccord Genuity Group cut their target price on Teladoc Health from $28.00 to $25.00 and set a buy rating for the company in a research report on Friday. Finally, SVB Leerink began coverage on Teladoc Health in a research report on Monday, February 26th. They issued a market perform rating and a $17.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $19.67.

Insider Activity at Teladoc Health

In related news, CAO Richard J. Napolitano sold 3,765 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the sale, the chief accounting officer now owns 18,077 shares of the company’s stock, valued at approximately $262,478.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Teladoc Health news, EVP Andrew Turitz sold 6,190 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $89,878.80. Following the completion of the transaction, the executive vice president now directly owns 39,429 shares in the company, valued at approximately $572,509.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Richard J. Napolitano sold 3,765 shares of Teladoc Health stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the transaction, the chief accounting officer now owns 18,077 shares in the company, valued at approximately $262,478.04. The disclosure for this sale can be found here. Insiders sold a total of 135,441 shares of company stock valued at $2,038,251 in the last quarter. Insiders own 1.63% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.